HUTCHMED (NASDAQ:HCM) Shares Gap Up – Time to Buy?

Posted by Geri Gentry on Oct 22nd, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report) gapped up prior to trading on Tuesday. The stock had previously closed at $14.18, but opened at $14.69. HUTCHMED shares last traded at $14.8050, with a volume of 14,904 shares trading hands.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on HCM shares. Wall Street Zen raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HSBC upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. The Goldman Sachs Group cut their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a “neutral” rating on the stock in a research report on Thursday, July 23rd. Weiss Ratings raised shares of HUTCHMED from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Finally, Daiwa Securities Group upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Thursday, September 3rd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.87.

Check Out Our Latest Analysis on HCM

HUTCHMED Price Performance

The stock’s 50 day moving average price is $13.49 and its 200 day moving average price is $12.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM – Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The company had revenue of $139.14 million during the quarter, compared to analyst estimates of $304.16 million. On average, sell-side analysts expect that HUTCHMED will post 0.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Amundi increased its position in shares of HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company’s stock worth $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of HUTCHMED by 25.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company’s stock worth $1,553,000 after purchasing an additional 21,270 shares in the last quarter. XY Capital Ltd boosted its holdings in shares of HUTCHMED by 115.2% in the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after buying an additional 55,736 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of HUTCHMED in the 1st quarter valued at approximately $365,000. 8.82% of the stock is currently owned by institutional investors.

HUTCHMED Company Profile

(Get Free Report)

HUTCHMED (NASDAQ:HCM) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines research and development capabilities in China with international development and commercial operations, serving patients and healthcare providers in China, the United States, Europe and other global markets.

HUTCHMED’s oncology portfolio includes fruquintinib, a targeted therapy for certain patients with metastatic colorectal cancer.